

Stefano Del Prato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4975320/publications.pdf>

Version: 2024-02-01

452
papers

34,680
citations

4370

86
h-index

4419

172
g-index

462
all docs

462
docs citations

462
times ranked

37017
citing authors

#	ARTICLE	IF	CITATIONS
1	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>European Heart Journal</i> , 2012, 33, 1635-1701.	1.0	5,247
2	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. <i>Lancet, The</i> , 2014, 383, 1068-1083.	6.3	1,230
3	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 1519-1529.	6.3	1,179
4	How Do We Define Cure of Diabetes?. <i>Diabetes Care</i> , 2009, 32, 2133-2135.	4.3	852
5	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. <i>Diabetes Care</i> , 2016, 39, 861-877.	4.3	718
6	Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. <i>Journal of Clinical Investigation</i> , 2007, 117, 2155-2163.	3.9	683
7	COVID-19 in people with diabetes: understanding the reasons for worse outcomes. <i>Lancet Diabetes and Endocrinology, the</i> , 2020, 8, 782-792.	5.5	668
8	New-Onset Diabetes in Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 789-790.	13.9	624
9	Prolonged Exposure to Free Fatty Acids Has Cytostatic and Pro-Apoptotic Effects on Human Pancreatic Islets: Evidence that β -Cell Death Is Caspase Mediated, Partially Dependent on Ceramide Pathway, and Bcl-2 Regulated. <i>Diabetes</i> , 2002, 51, 1437-1442.	0.3	547
10	Coxsackie B4 virus infection of beta cells and natural killer cell insulinitis in recent-onset type 1 diabetic patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 5115-5120.	3.3	521
11	Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin. <i>Diabetes Care</i> , 2011, 34, 2015-2022.	4.3	479
12	Management of type 2 diabetes: new and future developments in treatment. <i>Lancet, The</i> , 2011, 378, 182-197.	6.3	459
13	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology, the</i> , 2021, 9, 653-662.	5.5	437
14	Functional and Molecular Defects of Pancreatic Islets in Human Type 2 Diabetes. <i>Diabetes</i> , 2005, 54, 727-735.	0.3	421
15	Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. <i>Diabetologia</i> , 2008, 51, 615-622.	2.9	421
16	The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 5-14.	2.2	398
17	Cardiovascular and Renal Outcomes with Efglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 896-907.	13.9	339
18	Obesity and insulin resistance in humans: A dose-response study. <i>Metabolism: Clinical and Experimental</i> , 1990, 39, 452-459.	1.5	333

#	ARTICLE	IF	CITATIONS
19	Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. <i>Diabetologia</i> , 2005, 48, 282-289.	2.9	322
20	Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a preplanned meta-analysis of phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 175-184.	2.2	309
21	Pancreatic Islets from Type 2 Diabetic Patients Have Functional Defects and Increased Apoptosis That Are Ameliorated by Metformin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5535-5541.	1.8	304
22	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. <i>Lancet, The</i> , 2012, 379, 1498-1507.	6.3	304
23	Intermediate metabolism in normal pregnancy and in gestational diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 259-270.	1.7	285
24	Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. <i>Diabetologia</i> , 1994, 37, 1025-1035.	2.9	280
25	Effect of linagliptin monotherapy on glycaemic control and markers of β^2 -cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 258-267.	2.2	274
26	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 1811-1824.	6.3	257
27	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. <i>Diabetes Care</i> , 2016, 39, 717-725.	4.3	244
28	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017, 5, 887-897.	5.5	231
29	Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2019, 394, 1519-1529.	6.3	210
30	Maternal triglyceride levels and newborn weight in pregnant women with normal glucose tolerance. <i>Diabetic Medicine</i> , 2005, 22, 21-25.	1.2	206
31	The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2001, 17, 164-174.	1.7	197
32	Reducing insulin resistance with metformin: the evidence today. <i>Diabetes and Metabolism</i> , 2003, 29, 6S28-6S35.	1.4	194
33	Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 581-590.	2.2	189
34	Phasic Insulin Release and Metabolic Regulation in Type 2 Diabetes. <i>Diabetes</i> , 2002, 51, S109-S116.	0.3	183
35	COVID-19, Hyperglycemia, and New-Onset Diabetes. <i>Diabetes Care</i> , 2021, 44, 2645-2655.	4.3	164
36	Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005, 15, 250-254.	1.1	161

#	ARTICLE	IF	CITATIONS
37	Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. <i>Diabetes</i> , 1999, 48, 99-105.	0.3	156
38	Prevalence and risk factors for gestational diabetes assessed by universal screening. <i>Diabetes Research and Clinical Practice</i> , 2003, 62, 131-137.	1.1	156
39	Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. <i>Diabetic Medicine</i> , 2009, 26, 1185-1192.	1.2	156
40	Lipotoxicity in Human Pancreatic Islets and the Protective Effect of Metformin. <i>Diabetes</i> , 2002, 51, S134-S137.	0.3	155
41	Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus.. <i>Journal of Clinical Investigation</i> , 1993, 91, 484-494.	3.9	152
42	Cystatin C and Estimates of Renal Function: Searching for a Better Measure of Kidney Function in Diabetic Patients. <i>Clinical Chemistry</i> , 2007, 53, 480-488.	1.5	151
43	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. <i>Diabetes Care</i> , 2020, 43, 1695-1703.	4.3	147
44	Insulin Resistance in Cushing's Syndrome*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983, 57, 529-536.	1.8	146
45	Role of Tissue-Specific Blood Flow and Tissue Recruitment in Insulin-Mediated Glucose Uptake of Human Skeletal Muscle. <i>Circulation</i> , 1998, 98, 234-241.	1.6	145
46	Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 640-648.	5.5	139
47	Effects of glucosamine infusion on insulin secretion and insulin action in humans. <i>Diabetes</i> , 2000, 49, 926-935.	0.3	136
48	Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPAR β in the modulation of insulin secretion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E560-E567.	1.8	134
49	Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes.. <i>Journal of Clinical Investigation</i> , 1993, 92, 486-494.	3.9	134
50	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2532-2540.	2.2	133
51	Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. <i>Diabetes Care</i> , 2020, 43, 2345-2348.	4.3	133
52	Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2013, 36, 1779-1788.	4.3	130
53	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 1144-1162.	1.0	126
54	A Common Polymorphism in the Promoter of UCP2 Contributes to the Variation in Insulin Secretion in Glucose-Tolerant Subjects. <i>Diabetes</i> , 2003, 52, 1280-1283.	0.3	125

#	ARTICLE	IF	CITATIONS
55	In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. <i>Diabetic Medicine</i> , 2008, 25, 326-332.	1.2	124
56	Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal. <i>International Journal of Clinical Practice</i> , 2005, 59, 1345-1355.	0.8	123
57	Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. <i>Diabetologia</i> , 2004, 47, 300-303.	2.9	122
58	Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?. <i>Diabetes Care</i> , 2014, 37, 1499-1508.	4.3	122
59	Megatrials in type 2 diabetes. From excitement to frustration?. <i>Diabetologia</i> , 2009, 52, 1219-1226.	2.9	118
60	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations. <i>Obesity Surgery</i> , 2017, 27, 2-21.	1.1	118
61	What does postprandial hyperglycaemia mean?. <i>Diabetic Medicine</i> , 2004, 21, 208-213.	1.2	114
62	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. <i>Diabetes and Metabolism</i> , 2007, 33, 129-134.	1.4	114
63	Effect of Metformin on Insulin-Stimulated Glucose Turnover and Insulin Binding to Receptors in Type II Diabetes. <i>Diabetes Care</i> , 1987, 10, 62-67.	4.3	113
64	Semiquantitative Analysis of the Histopathological Features of the Neuropathic Foot Ulcer: Effects of pressure relief. <i>Diabetes Care</i> , 2003, 26, 3123-3128.	4.3	113
65	Hepatitis C Virus Infection and Human Pancreatic β -Cell Dysfunction. <i>Diabetes Care</i> , 2005, 28, 940-941.	4.3	113
66	The place of sulfonylureas in the therapy for type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, S20-S27.	1.5	112
67	Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. <i>European Journal of Clinical Investigation</i> , 2000, 30, 45-52.	1.7	109
68	A telemedicine support for diabetes management: the T-IDDM project. <i>Computer Methods and Programs in Biomedicine</i> , 2002, 69, 147-161.	2.6	109
69	Serum Haptoglobin: A Novel Marker of Adiposity in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2678-2683.	1.8	109
70	Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients. <i>Diabetologia</i> , 2006, 49, 2977-2982.	2.9	109
71	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. <i>Diabetes Care</i> , 2017, 40, 813-820.	4.3	109
72	An Off-the-Shelf Instant Contact Casting Device for the Management of Diabetic Foot Ulcers: A randomized prospective trial versus traditional fiberglass cast. <i>Diabetes Care</i> , 2007, 30, 586-590.	4.3	108

#	ARTICLE	IF	CITATIONS
73	Review of methods for detecting glycemic disorders. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108233.	1.1	108
74	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY 4 randomised trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1781-1792.	2.2	105
75	The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. <i>Diabetes/Metabolism Research and Reviews</i> , 2010, 26, 239-244.	1.7	104
76	Insulin Secretory Function Is Impaired in Isolated Human Islets Carrying the Gly972->Arg IRS-1 Polymorphism. <i>Diabetes</i> , 2002, 51, 1419-1424.	0.3	103
77	Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 234-238.	1.7	103
78	Beta- and Alpha-Cell Dysfunction in Type 2 Diabetes. <i>Hormone and Metabolic Research</i> , 2004, 36, 775-781.	0.7	97
79	Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction. <i>Diabetologia</i> , 2012, 55, 1847-1855.	2.9	95
80	Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1111-1120.	2.2	93
81	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. <i>Diabetologia</i> , 2022, 65, 1251-1261.	2.9	93
82	Glucose tolerance is negatively associated with circulating progenitor cell levels. <i>Diabetologia</i> , 2007, 50, 2156-2163.	2.9	92
83	Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β -Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2100-2105.	1.8	92
84	Low-Grade Inflammation and Microalbuminuria in Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2414-2419.	1.1	91
85	Effects of pancreas-kidney transplantation on diabetic retinopathy. <i>Transplant International</i> , 2005, 18, 619-622.	0.8	90
86	Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17,000 patients. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1085-1092.	2.2	89
87	Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. <i>Diabetes</i> , 1999, 48, 1316-1322.	0.3	88
88	The Beneficial Effects of Pancreas Transplant Alone on Diabetic Nephropathy. <i>Diabetes Care</i> , 2005, 28, 1366-1370.	4.3	88
89	Rationale, design, and baseline characteristics in Evaluation of Lixisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
90	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation. <i>Journal of Hypertension</i> , 2012, 30, 1056-1064.	0.3	86

#	ARTICLE	IF	CITATIONS
91	Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance. <i>Diabetologia</i> , 1997, 40, 687-697.	2.9	84
92	New forms of insulin and insulin therapies for the treatment of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 638-652.	5.5	84
93	Hyperglucagonemia and insulin-mediated glucose metabolism.. <i>Journal of Clinical Investigation</i> , 1987, 79, 547-556.	3.9	84
94	Exogenous and Endogenous Postprandial Lipid Abnormalities in Type 2 Diabetic Patients with Optimal Blood Glucose Control and Optimal Fasting Triglyceride Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2153-2159.	1.8	83
95	The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. <i>European Journal of Endocrinology</i> , 2006, 154, 355-361.	1.9	80
96	Early Left Ventricular Mechanics Abnormalities in Prehypertension: A Two-Dimensional Strain Echocardiography Study. <i>American Journal of Hypertension</i> , 2010, 23, 405-412.	1.0	80
97	In search of normoglycaemia in diabetes: controlling postprandial glucose. <i>International Journal of Obesity</i> , 2002, 26, S9-S17.	1.6	79
98	'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) <i>Tj ETQq0 0 Q rgBT /Overlock 10 T</i>	1.6	79
99	Prevention & Rehabilitation (EACPR). [<i>Eur Heart J</i> 2012;33:1635-1701, doi: 10.1093/eurheartj/ehs092]. <i>European Heart Journal</i> , 2012, 33, 2126-2126.	0.2	77
100	Increased O-glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic Î²-cells. <i>FASEB Journal</i> , 2004, 18, 959-961.	1.7	76
101	C-reactive protein and metabolic syndrome in women with previous gestational diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 135-140.	2.2	76
102	Alirocumab vs usual lipid-lowering care as addition to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY 4 DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1479-1489.	1.1	74
103	Ace/Aace Consensus Conference on The Implementation of Outpatient Management of Diabetes Mellitus: Consensus Conference Recommendations. <i>Endocrine Practice</i> , 2006, 12, 6-12.	0.3	73
104	Cardiovascular risk assessment in low-resource settings. <i>Journal of Hypertension</i> , 2014, 32, 951-960.	3.9	72
105	Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals.. <i>Journal of Clinical Investigation</i> , 1996, 98, 108-115.	0.5	72
106	PANCREAS PRESERVATION WITH UNIVERSITY OF WISCONSIN AND CELSIOR SOLUTIONS: A SINGLE-CENTER, PROSPECTIVE, RANDOMIZED PILOT STUDY. <i>Transplantation</i> , 2004, 77, 1186-1190.	1.4	72
107	Î²-cell apoptosis in type 2 diabetes: quantitative and functional consequences. <i>Diabetes and Metabolism</i> , 2008, 34, S56-S64.	1.1	71
108	Unresectable hepatocellular carcinoma in cirrhosis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 2332-2339.	1.2	71
108	Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. <i>Journal of Diabetes and Its Complications</i> , 2005, 19, 60-64.		

#	ARTICLE	IF	CITATIONS
109	Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 155 mg/dl (8.6 mmol/L). <i>Diabetes Research and Clinical Practice</i> , 2018, 146, 18-33.	1.1	71
110	Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. <i>European Journal of Clinical Investigation</i> , 2001, 31, 603-609.	1.7	70
111	Insulin Resistance Is Independently Associated With Postprandial Alterations of Triglyceride-Rich Lipoproteins in Type 2 Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2397-2402.	1.1	69
112	Cell function and anti-diabetic pharmacotherapy. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 518-527.	1.7	68
113	Normal Glucose Tolerance and Gestational Diabetes Mellitus: What is in between?. <i>Diabetes Care</i> , 2007, 30, 1783-1788.	4.3	67
114	Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 624-631.	1.1	67
115	Plasma Free Fatty Acids and Endothelium-Dependent Vasodilation: Effect of Chain-Length and Cyclooxygenase Inhibition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 793-798.	1.8	64
116	Activation of the Hexosamine Pathway Leads to Phosphorylation of Insulin Receptor Substrate-1 on Ser307 and Ser612 and Impairs the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Insulin Biosynthetic Pathway in RIN Pancreatic β -Cells. <i>Endocrinology</i> , 2004, 145, 2845-2857.	1.4	64
117	Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1239-1246.	2.2	64
118	Brain function rescue effect of lactate following hypoglycaemia is not an adaptation process in both normal and Type I diabetic subjects. <i>Diabetologia</i> , 2000, 43, 733-741.	2.9	63
119	Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid Metabolic Syndrome. <i>Atherosclerosis</i> , 2004, 172, 383-389.	0.4	63
120	Identification of cathepsin K as a novel marker of adiposity in white adipose tissue. <i>Journal of Cellular Physiology</i> , 2003, 195, 309-321.	2.0	62
121	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2022, 145, 565-574.	1.6	59
122	Insulin regulation of glucose and lipid metabolism in massive obesity. <i>Diabetologia</i> , 1990, 33, 228-236.	2.9	58
123	A simplified technique for the en bloc procurement of abdominal organs that is suitable for pancreas and small-bowel transplantation. <i>Surgery</i> , 2004, 135, 629-641.	1.0	58
124	Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. <i>International Journal of Clinical Practice</i> , 2010, 64, 295-304.	0.8	58
125	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. <i>Diabetes Care</i> , 2014, 37, 2647-2659.	4.3	58
126	Treatment of Patients Over 64 Years of Age With Type 2 Diabetes: Experience from nateglinide pooled database retrospective analysis. <i>Diabetes Care</i> , 2003, 26, 2075-2080.	4.3	57

#	ARTICLE	IF	CITATIONS
127	G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: The role of type 2 diabetes and fatty acids. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 22-25.	1.1	56
128	Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man. <i>International Journal of Obesity</i> , 1999, 23, 1307-1313.	1.6	55
129	Cystatin C as a marker of renal function immediately after liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 285-291.	1.3	55
130	Metabolic Syndrome and Vascular Alterations in Normotensive Subjects at Risk of Diabetes Mellitus. <i>Hypertension</i> , 2008, 51, 440-445.	1.3	55
131	Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 610-614.	1.8	54
132	Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 898-905.	1.1	54
133	Treating the metabolic syndrome. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 491-506.	0.6	53
134	Concomitance of Diabetic Retinopathy and Proteinuria Accelerates the Rate of Decline of Kidney Function in Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2002, 25, 2026-2031.	4.3	52
135	The pancreatic beta-cell in human Type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, S3-S6.	1.1	51
136	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitusâ€”Rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2018, 203, 30-38.	1.2	51
137	Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. <i>Diabetes</i> , 1996, 45, 915-925.	0.3	51
138	A call to action - the UN Resolution on diabetes. <i>International Journal of Clinical Practice</i> , 2007, 61, 1-4.	0.8	50
139	Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 2108-2116.	4.3	50
140	Immune Checkpoint Blockade Antiâ€”PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome. <i>Journal of the Endocrine Society</i> , 2019, 3, 496-503.	0.1	50
141	Metabolic Memory and Individual Treatment Aims in Type 2 Diabetes â€” Outcome-Lessons Learned from Large Clinical Trials. <i>Review of Diabetic Studies</i> , 2011, 8, 432-440.	0.5	50
142	Insulin secretion defects of human type 2 diabetic islets are corrected in vitro by a new reactive oxygen species scavenger. <i>Diabetes and Metabolism</i> , 2007, 33, 340-345.	1.4	49
143	Use of Insulin Glargine During the First Weeks of Pregnancy in Five Type 1 Diabetic Women. <i>Diabetes Care</i> , 2005, 28, 982-983.	4.3	48
144	Î²-cell failure in type 2 diabetes mellitus. <i>Current Diabetes Reports</i> , 2008, 8, 179-184.	1.7	47

#	ARTICLE	IF	CITATIONS
145	Telecare Provides Comparable Efficacy to Conventional Self-Monitored Blood Glucose in Patients with Type 2 Diabetes Titrating One Injection of Insulin Glulisine—the ELEONOR Study. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 175-182.	2.4	46
146	Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. <i>Diabetes</i> , 1995, 44, 165-172.	0.3	46
147	Maternal Metabolic Control and Perinatal Outcome in Women With Gestational Diabetes Mellitus Treated With Lispro or Aspart Insulin: Comparison with regular insulin. <i>Diabetes Care</i> , 2007, 30, e11-e11.	4.3	45
148	Left Ventricular Function in Normotensive Young Adults With Well-Controlled Type 1 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2007, 99, 84-90.	0.7	45
149	A Randomized Controlled Trial to Examine the Efficacy and Safety of a New Super-Oxidized Solution for the Management of Wide Postsurgical Lesions of the Diabetic Foot. <i>International Journal of Lower Extremity Wounds</i> , 2010, 9, 10-15.	0.6	45
150	Long-Term (5 Years) Efficacy and Safety of Pancreas Transplantation Alone in Type 1 Diabetic Patients. <i>Transplantation</i> , 2012, 93, 842-846.	0.5	45
151	Effects of exendin-4 on islets from type 2 diabetes patients. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 515-519.	2.2	44
152	Oxidative stress in response to high glucose levels in endothelial cells and in endothelial progenitor cells. <i>Microvascular Research</i> , 2010, 80, 332-338.	1.1	44
153	Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. <i>Cardiovascular Diabetology</i> , 2016, 15, 111.	2.7	44
154	Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 560-568.	2.2	43
155	Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study. <i>Cardiovascular Diabetology</i> , 2019, 18, 159.	2.7	43
156	The Presence of Retinopathy in Patients with Secondary Diabetes Following Pancreatectomy or Chronic Pancreatitis. <i>Diabetes Care</i> , 1983, 6, 570-574.	4.3	42
157	Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 997-1006.	1.1	42
158	Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. <i>Diabetes Care</i> , 2015, 38, 2293-2300.	4.3	42
159	Influence of dietary fat and carbohydrates proportions on plasma lipids, glucose control and low-grade inflammation in patients with type 2 diabetes—the TOSCA.IT Study. <i>European Journal of Nutrition</i> , 2016, 55, 1645-1651.	1.8	42
160	Optimal therapy of type 2 diabetes: a controversial challenge. <i>Aging</i> , 2014, 6, 187-206.	1.4	41
161	The contribution of hyperglycaemia and hypoinsulinaemia to the insulin resistance of streptozotocin-diabetic rats. <i>Diabetologia</i> , 1992, 35, 310-315.	2.9	40
162	High blood ketone body concentration in Type 2 non-insulin dependent diabetic patients. <i>Journal of Endocrinological Investigation</i> , 1996, 19, 99-105.	1.8	40

#	ARTICLE	IF	CITATIONS
163	Pancreas transplant alone determines early improvement of cardiovascular risk factors and cardiac function in type 1 diabetic patients. <i>Transplantation</i> , 2003, 76, 974-976.	0.5	40
164	Earlier intervention in type 2 diabetes: The case for achieving early and sustained glycaemic control. <i>International Journal of Clinical Practice</i> , 2005, 59, 1309-1316.	0.8	40
165	Modulation of palmitic acid-induced cell death by ergothioneine: Evidence of an anti-inflammatory action. <i>BioFactors</i> , 2008, 33, 237-247.	2.6	40
166	Primary Prevention of Cardiovascular Disease in People With Dysglycemia. <i>Diabetes Care</i> , 2008, 31, S208-S214.	4.3	40
167	Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 571-579.	1.1	40
168	Multidrug Treatment of Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, S231-S235.	4.3	39
169	Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?. <i>Current Diabetes Reports</i> , 2013, 13, 403-410.	1.7	39
170	Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 397-409.	0.9	39
171	Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. <i>Diabetologia</i> , 2017, 60, 1102-1113.	2.9	38
172	Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 361-373.	1.1	37
173	Type 1 diabetes and COVID-19: The "lockdown effect". <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108468.	1.1	37
174	Insulin resistance and diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 1996, 10, 243-245.	1.2	36
175	Pathogenetic Mechanisms and Cardiovascular Risk. <i>Diabetes Care</i> , 2012, 35, 2607-2612.	4.3	36
176	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. <i>International Journal of Clinical Practice</i> , 2012, 66, 731-740.	0.8	36
177	Physical activity, depressed mood and pregnancy worries in European obese pregnant women: results from the DALI study. <i>BMC Pregnancy and Childbirth</i> , 2015, 15, 158.	0.9	36
178	Reinterpreting Cardiorenal Protection of Renal Sodium-Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming. <i>Diabetes Care</i> , 2020, 43, 501-507.	4.3	36
179	beta-Cell mass plasticity in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2004, 6, 319-331.	2.2	35
180	Continually high insulin levels impair Akt phosphorylation and glucose transport in human myoblasts. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1687-1693.	1.5	35

#	ARTICLE	IF	CITATIONS
181	Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin. <i>Atherosclerosis</i> , 2008, 197, 346-354.	0.4	35
182	Study to determine the durability of glycaemic control with early treatment with a vildagliptin+metformin combination regimen vs. standard-of-care metformin monotherapy”the <sc>VERIFY</sc> trial: a randomized double-blind trial. <i>Diabetic Medicine</i> , 2014, 31, 1178-1184.	1.2	35
183	Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. <i>Diabetes</i> , 1997, 46, 1040-1046.	0.3	35
184	Early Subclinical Atherosclerosis in Women With Previous Gestational Diabetes Mellitus. <i>Diabetes Care</i> , 2008, 31, e32-e32.	4.3	34
185	Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 760-766.	2.2	34
186	Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 1568-1574.	1.8	34
187	PPARG2 Pro12Ala and ADAMTS9 rs4607103 as insulin resistance loci and insulin secretion loci in Italian individuals. The GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4. <i>Acta Diabetologica</i> , 2013, 50, 401-408.	1.2	33
188	Pre-pregnancy obesity, gestational diabetes or gestational weight gain: Which is the strongest predictor of pregnancy outcomes?. <i>Diabetes Research and Clinical Practice</i> , 2018, 144, 286-293.	1.1	33
189	Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 252-260.	2.2	33
190	Results of Pancreas Transplantation Alone with Special Attention to Native Kidney Function and Proteinuria in Type 1 Diabetes Patients. <i>Review of Diabetic Studies</i> , 2011, 8, 259-267.	0.5	32
191	Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 107-115.	2.2	32
192	Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 202-206.	2.2	32
193	Changing the Treatment Paradigm for Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, S217-S222.	4.3	31
194	Gender difference in diabetes-associated risk of first-ever and recurrent ischemic stroke. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 713-717.	1.2	31
195	Beliefs, Barriers, and Preferences of European Overweight Women to Adopt a Healthier Lifestyle in Pregnancy to Minimize Risk of Developing Gestational Diabetes Mellitus: An Explorative Study. <i>Journal of Pregnancy</i> , 2016, 2016, 1-11.	1.1	31
196	Metabolic regulation of GLP-1 and PC1/3 in pancreatic β -cell line. <i>PLoS ONE</i> , 2017, 12, e0187836.	1.1	31
197	Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?. <i>Diabetes Care</i> , 2021, 44, 647-654.	4.3	31
198	A Fermented Whole Grain Prevents Lipopolysaccharides-Induced Dysfunction in Human Endothelial Progenitor Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-13.	1.9	29

#	ARTICLE	IF	CITATIONS
199	Early Improvement of Unstable Diabetic Retinopathy After Solitary Pancreas Transplantation. <i>Diabetes Care</i> , 2002, 25, 2358-2359.	4.3	28
200	Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. <i>Acta Diabetologica</i> , 2003, 40, 20-27.	1.2	28
201	Tackling Hyperglycemia: A More Comprehensive Approach. <i>Endocrine Practice</i> , 2006, 12, 63-66.	1.1	28
202	The non-peptidyl low molecular weight radical scavenger IAC protects human pancreatic islets from lipotoxicity. <i>Molecular and Cellular Endocrinology</i> , 2009, 309, 63-66.	1.6	28
203	Grain and Bean Lysates Improve Function of Endothelial Progenitor Cells from Human Peripheral Blood: Involvement of the Endogenous Antioxidant Defenses. <i>PLoS ONE</i> , 2014, 9, e109298.	1.1	28
204	Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people. <i>Primary Care Diabetes</i> , 2019, 13, 330-352.	0.9	28
205	Impact of COVID-19 lockdown on glucose control of elderly people with type 2 diabetes in Italy. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108750.	1.1	28
206	From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 92.	2.7	28
207	Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future. <i>Diabetes Therapy</i> , 2021, 12, 2289-2310.	1.2	28
208	A fully implantable device for intraperitoneal drug delivery refilled by ingestible capsules. <i>Science Robotics</i> , 2021, 6, .	9.9	28
209	Effect of insulin replacement on intermediary metabolism in diabetes secondary to pancreatectomy. <i>Diabetologia</i> , 1983, 25, 252-259.	2.9	27
210	Biochemical and ultrasound tests for early diagnosis of active neuro-osteoarthropathy (NOA) of the diabetic foot. <i>Diabetes Research and Clinical Practice</i> , 2002, 58, 1-9.	1.1	27
211	Gestational diabetes, inflammation, and late vascular disease. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 873-879.	1.8	27
212	Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes. <i>Diabetes Care</i> , 2009, 32, S342-S348.	4.3	27
213	Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. <i>Atherosclerosis</i> , 2018, 276, 124-130.	0.4	27
214	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. <i>Cardiovascular Diabetology</i> , 2019, 18, 149.	2.7	27
215	Basal weekly insulins: the way of the future!. <i>Metabolism: Clinical and Experimental</i> , 2022, 126, 154924.	1.5	27
216	Mechanisms of fasting hypoglycemia and concomitant insulin resistance in insulinoma patients. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 24-29.	1.5	26

#	ARTICLE	IF	CITATIONS
217	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 399-414.	0.9	26
218	The incretin/glucagon system as a target for pharmacotherapy of obesity. <i>Obesity Reviews</i> , 2022, 23, .	3.1	26
219	Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in Type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents. <i>Diabetologia</i> , 1990, 33, 688-695.	2.9	25
220	Universal screening and intensive metabolic management of gestational diabetes: cost-effectiveness in Italy. <i>Acta Diabetologica</i> , 2002, 39, 69-73.	1.2	25
221	Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, 246-253.	1.1	25
222	Optimizing management of metabolic syndrome to reduce risk: focus on life-style. <i>Internal and Emergency Medicine</i> , 2008, 3, 87-98.	1.0	25
223	Effect of diabetes on hospitalization for ischemic stroke and related in-hospital mortality: a study in Tuscany, Italy, over years 2004-2011. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 280-286.	1.7	25
224	Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. <i>Drugs</i> , 2017, 77, 247-264.	4.9	25
225	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017, 16, 70.	2.7	25
226	Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. <i>Diabetes Care</i> , 2021, 44, 1062-1069.	4.3	25
227	Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. <i>Diabetes</i> , 1998, 47, 1347-1353.	0.3	25
228	The antiketogenic effect of alanine in normal man: Evidence for an alanine-ketone body cycle. <i>Metabolism: Clinical and Experimental</i> , 1981, 30, 563-567.	1.5	24
229	Measurement of Insulin Resistance In Vivo. <i>Drugs</i> , 1999, 58, 3-6.	4.9	24
230	Elevated non-esterified fatty acids impair nitric oxide independent vasodilation, in humans: evidence for a role of inwardly rectifying potassium channels. <i>Atherosclerosis</i> , 2003, 169, 147-153.	0.4	24
231	The role of peripheral benzodiazepine receptors on the function and survival of isolated human pancreatic islets. <i>European Journal of Endocrinology</i> , 2004, 151, 207-214.	1.9	24
232	The TOSCA.IT Trial: A Study Designed to Evaluate the Effect of Pioglitazone Versus Sulfonylureas on Cardiovascular Disease in Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, e82-e82.	4.3	24
233	Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: A meta-analysis of observational studies. <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 109066.	1.1	24
234	Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men. <i>Journal of Hypertension</i> , 2007, 25, 1389-1395.	0.3	23

#	ARTICLE	IF	CITATIONS
235	Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 136-144.	2.2	23
236	Efficacy and safety of once-monthly epeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1176-1186.	2.2	23
237	Effect of acute ketosis on the endothelial function of type 1 diabetic patients: the role of nitric oxide. <i>Diabetes</i> , 1999, 48, 391-397.	0.3	22
238	The metabolic syndrome is related to albuminuria in Type 2 diabetes. <i>Diabetic Medicine</i> , 2008, 25, 1412-1418.	1.2	22
239	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , 2020, 19, 14.	2.7	22
240	Ethanol impairs insulin-mediated glucose uptake by an indirect mechanism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2285-2290.	1.8	22
241	Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, 246-251.	1.7	21
242	Disappearance of Nephrotic Syndrome in Type 1 Diabetic Patients Following Pancreas Transplant Alone. <i>Transplantation</i> , 2006, 81, 1067-1068.	0.5	21
243	Peripheral wave reflection and endothelial function in untreated essential hypertensive patients with and without the metabolic syndrome. <i>Journal of Hypertension</i> , 2008, 26, 1216-1222.	0.3	21
244	Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 161.	1.1	21
245	Heterogeneity of diabetes: heralding the era of precision medicine. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 659-661.	5.5	21
246	Invited review. Series: Implications of the recent CVOTs in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108112.	1.1	21
247	Glucose Turnover and Recycling in Diabetes Secondary to Total Pancreatectomy: Effect of Glucagon Infusion*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 1023-1029.	1.8	20
248	The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. <i>Coronary Artery Disease</i> , 2005, 16, 67-73.	0.3	20
249	Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2023-2028.	2.2	20
250	Altered Visual Plasticity in Morbidly Obese Subjects. <i>IScience</i> , 2019, 22, 206-213.	1.9	20
251	Freestyle Libre trend arrows for the management of adults with insulin-treated diabetes: A practical approach. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 6-12.	1.2	20
252	Diabetes and acute bacterial skin and skin structure infections. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108732.	1.1	20

#	ARTICLE	IF	CITATIONS
253	Insulin sensitivity, binding, and kinetics in pancreatogenic and type I diabetes. <i>Diabetes</i> , 1982, 31, 346-355.	0.3	20
254	In situ protein Kinase C activity is increased in cultured fibroblasts from Type 1 diabetic patients with nephropathy. <i>Diabetologia</i> , 2003, 46, 524-530.	2.9	19
255	Chlorthalidone Improves Endothelial-Mediated Vascular Responses in Hypertension Complicated by Nondiabetic Metabolic Syndrome. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005, 10, 265-272.	1.0	19
256	Effects of C-peptide on isolated human pancreatic islet cells. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 215-219.	1.7	19
257	Selective screening for GDM in Italy: application and effectiveness of National Guidelines. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 28, 1842-1844.	0.7	18
258	Practical strategies for improving outcomes in <sc>T2DM</sc>: <sc>T</sc>he potential role of pioglitazone and <sc>DPP4</sc> inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 786-799.	2.2	18
259	Metabolic effects of moderate alcohol intake with meals in insulin-dependent diabetics controlled by artificial endocrine pancreas (AEP) and in normal subjects. <i>Metabolism: Clinical and Experimental</i> , 1983, 32, 463-470.	1.5	17
260	Kidney and pancreas transplants in Jehovah's witnesses: ethical and practical implications. <i>Transplantation Proceedings</i> , 2004, 36, 601-602.	0.3	17
261	Î±-Adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria. <i>Journal of Hypertension</i> , 2006, 24, 931-937.	0.3	17
262	Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 31-38.	1.1	17
263	What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. <i>Diabetes and Vascular Disease Research</i> , 2009, 6, 283-287.	0.9	17
264	Physical activity and dietary habits during pregnancy: effects on glucose tolerance. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2010, 23, 1310-1314.	0.7	17
265	Optimizing Insulin Glargine Plus One Injection of Insulin Glulisine in Type 2 Diabetes in the ELEONOR Study. <i>Diabetes Care</i> , 2011, 34, 2524-2526.	4.3	17
266	The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 599-606.	1.2	17
267	Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: <i>P</i> analysis of concomitant add&on versus sequential add&on to metformin and of triple versus dual therapy with metformin. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1542-1546.	2.2	17
268	Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. <i>Diabetologia</i> , 2020, 63, 2423-2433.	2.9	17
269	Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154242.	1.5	17
270	Predictors of post-traumatic complication of mild brain injury in anticoagulated patients: DOACs are safer than VKAs. <i>Internal and Emergency Medicine</i> , 2021, 16, 1061-1070.	1.0	17

#	ARTICLE	IF	CITATIONS
271	Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycaemic control and cardiovascular risk factors. <i>Journal of Diabetes and Its Complications</i> , 2007, 21, 20-27.	1.2	16
272	The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera [®] as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial. <i>Diabetic Medicine</i> , 2008, 25, 662-670.	1.2	16
273	Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 699-705.	1.1	16
274	Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycaemic control: Pooled analysis of data from three placebo-controlled phase III trials. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 274-279.	1.2	16
275	Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β -cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 834-839.	2.2	16
276	Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 883-892.	2.2	16
277	The IGFBP3/TMEM219 pathway regulates beta cell homeostasis. <i>Nature Communications</i> , 2022, 13, 684.	5.8	16
278	Glucagon levels and ketogenesis in human diabetes following total or partial pancreatectomy and severe chronic pancreatitis. <i>Acta Diabetologica Latina</i> , 1980, 17, 111-118.	0.2	15
279	Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 1196-1202.	1.5	15
280	Hyperglycaemia and cardiovascular risk. <i>Acta Diabetologica</i> , 2003, 40, s362-s369.	1.2	15
281	Targeting Insulin Resistance and β -Cell Dysfunction: The Role of Thiazolidinediones. <i>Diabetes Technology and Therapeutics</i> , 2004, 6, 719-731.	2.4	15
282	Continuous subcutaneous insulin infusion and multiple dose insulin injections in Type 1 diabetic pregnant women: a case-control study. <i>Gynecological Endocrinology</i> , 2010, 26, 193-196.	0.7	15
283	Access to emergency room for hypoglycaemia in people with diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 745-751.	1.7	15
284	Glucose Metabolism in High-Risk Subjects for Type 2 Diabetes Carrying the rs7903146TCF7L2Gene Variant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1160-E1167.	1.8	15
285	GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. <i>Acta Diabetologica</i> , 2015, 52, 1129-1133.	1.2	15
286	Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials. <i>Primary Care Diabetes</i> , 2016, 10, 51-59.	0.9	15
287	Gender difference in diabetes related excess risk of cardiovascular events: When does the "risk window" open?. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 74-79.	1.2	15
288	Effects of treatment with metformin and/or sitagliptin on β -cell function and insulin resistance in prediabetic women with previous gestational diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 648-657.	2.2	15

#	ARTICLE	IF	CITATIONS
289	Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 2465-2476.	1.2	15
290	Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. <i>Diabetes Care</i> , 2020, 43, 1065-1069.	4.3	15
291	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , 2021, 64, e7.	0.1	15
292	Metabolic control during total parenteral nutrition: Use of an artificial endocrine pancreas. <i>Metabolism: Clinical and Experimental</i> , 1988, 37, 510-513.	1.5	14
293	Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2001, 51, 97-105.	1.1	14
294	The metabolic syndrome. <i>Pharmacological Research</i> , 2006, 53, 457-468.	3.1	14
295	Soluble CD40 Ligand Levels in Essential Hypertensive Men: Evidence of a Possible Role of Insulin Resistance. <i>American Journal of Hypertension</i> , 2009, 22, 1007-1013.	1.0	14
296	Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 550-557.	1.2	14
297	ACE gene insertion/deletion polymorphism modulates capillary permeability in hypertension. <i>Clinical Science</i> , 2006, 111, 357-364.	1.8	13
298	Pharmacological intervention in prediabetes: considering the risks and benefits. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 17-22.	2.2	13
299	Insulin resistance and lipid disorders. <i>Future Lipidology</i> , 2008, 3, 651-664.	0.5	13
300	Beneficial Effect of the Nonpeptidyl Low Molecular Weight Radical Scavenger IAC on Cultured Human Islet Function. <i>Cell Transplantation</i> , 2008, 17, 1271-1276.	1.2	13
301	Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2014, 10, 465.	1.0	13
302	Personalized Therapy by Phenotype and Genotype. <i>Diabetes Care</i> , 2016, 39, S127-S136.	4.3	13
303	Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. <i>Diabetes Care</i> , 2020, 43, e139-e141.	4.3	13
304	Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 245-251.	2.2	13
305	Hepatic sensitivity to insulin: Effects of sulfonylurea drugs. <i>American Journal of Medicine</i> , 1991, 90, S29-S36.	0.6	12
306	Short-term effects of metformin on insulin sensitivity and sodium homeostasis in essential hypertensives. <i>Journal of Hypertension</i> , 1993, 11, S276-S277.	0.3	12

#	ARTICLE	IF	CITATIONS
307	What therapy do our NIDDM patients need? Insulin releasers. <i>Diabetes Research and Clinical Practice</i> , 1995, 28, S159-S165.	1.1	12
308	Rosiglitazone plus metformin: combination therapy for Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1411-1422.	0.9	12
309	Circulating endothelial progenitor cells in women with gestational alterations of glucose tolerance. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 202-210.	0.9	12
310	Evidence for a Role of Frataxin in Pancreatic Islets Isolated from Multi-Organ Donors with and Without Type 2 Diabetes Mellitus. <i>Hormone and Metabolic Research</i> , 2012, 44, 471-475.	0.7	12
311	Regulation of medical devices used in diabetology in Europe: Time for reform?. <i>Diabetologia</i> , 2012, 55, 2295-2297.	2.9	12
312	How conclusive is the CONCLUDE trial?. <i>Diabetologia</i> , 2020, 63, 692-697.	2.9	12
313	Design and baseline characteristics of the <sc>AMPLITUDEâ€œ</sc> cardiovascular outcomes trial of efpeglenatide, a weekly glucagonâ€like peptideâ€1 receptor agonist. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 318-323.	2.2	12
314	Glucagon-like peptide-1 secretion in women with gestational diabetes mellitus during and after pregnancy. <i>Journal of Endocrinological Investigation</i> , 2011, 34, e287-90.	1.8	12
315	Early detection of left ventricular dysfunction in diabetes mellitus patients with normal ejection fraction, stratified by BMI: A preliminary speckle tracking echocardiography study. <i>Journal of Cardiovascular Echography</i> , 2013, 23, 73.	0.1	12
316	The relationship between alanine and ketone body in vivo. <i>Metabolism: Clinical and Experimental</i> , 1982, 31, 1175-1178.	1.5	11
317	Microalbuminuria, a parameter independent of metabolic influences in hypertensive men. <i>Journal of Hypertension</i> , 2003, 21, 1163-1169.	0.3	11
318	Ninety-Five Percent Insulin Independence Rate 3 Years After Pancreas Transplantation Alone With Portal-Enteric Drainage. <i>Transplantation Proceedings</i> , 2005, 37, 1274-1277.	0.3	11
319	High insulin levels impair intracellular receptor trafficking in human cultured myoblasts. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, 316-323.	1.1	11
320	Lack of association between TGF- \hat{A} -1 genotypes and microalbuminuria in essential hypertensive men. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1864-1869.	0.4	11
321	Gender Effect on the Relation between Diabetes and Hospitalization for Heart Failure. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2012, 120, 51-55.	0.6	11
322	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 193-259.	1.8	11
323	Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial. <i>Journal of Diabetes Investigation</i> , 2018, 9, 579-586.	1.1	11
324	Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2564-2569.	2.2	11

#	ARTICLE	IF	CITATIONS
325	Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3296-3302.	1.8	11
326	Nesidioblastosis and Insulinoma: A Rare Coexistence and a Therapeutic Challenge. <i>Frontiers in Endocrinology</i> , 2020, 11, 10.	1.5	11
327	Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 177-186.	2.2	11
328	Insulin discovery: A pivotal point in medical history. <i>Metabolism: Clinical and Experimental</i> , 2022, 127, 154941.	1.5	11
329	Brain effect of bariatric surgery in people with obesity. <i>International Journal of Obesity</i> , 2022, 46, 1671-1677.	1.6	11
330	Insulin receptors on circulating blood cells from patients with pancreatogenic diabetes: a comparison with type I diabetes and normal subjects. <i>Journal of Endocrinological Investigation</i> , 1987, 10, 311-319.	1.8	10
331	Mechanisms of acute and chronic hypoglycemic action of gliclazide. <i>Acta Diabetologica</i> , 2000, 37, 201-206.	1.2	10
332	Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals. <i>Pharmacological Research</i> , 2005, 51, 561-565.	3.1	10
333	We have the evidence, we need to act to improve diabetes care. <i>International Journal of Clinical Practice</i> , 2007, 61, 9-15.	0.8	10
334	A Common Polymorphism in the Monocyte Chemoattractant Protein-1 (MCP-1) Gene Regulatory Region Influences MCP-1 Expression and Function of Isolated Human Pancreatic Islets. <i>Transplantation Proceedings</i> , 2010, 42, 2247-2249.	0.3	10
335	1-Hour OGTT Plasma Glucose as a Marker of Progressive Deterioration of Insulin Secretion and Action in Pregnant Women. <i>International Journal of Endocrinology</i> , 2012, 2012, 1-5.	0.6	10
336	Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 623-627.	2.2	10
337	Plasma N-Acetylaspartate Is Related to Age, Obesity, and Glucose Metabolism: Effects of Antidiabetic Treatment and Bariatric Surgery. <i>Frontiers in Endocrinology</i> , 2020, 11, 216.	1.5	10
338	Continuous subcutaneous insulin infusion and multiple dose insulin injections in Type 1 diabetic pregnant women: a case-control study. <i>Gynecological Endocrinology</i> , 2010, 26, 1-4.	0.7	10
339	Body Composition Study in The Elderly: Comparison Between Tritium Dilution Method and Dual Photon Absorptiometry. <i>Journal of Gerontology</i> , 1993, 48, M244-M248.	2.0	9
340	Cytochrome P450 2J2 Polymorphism in Healthy Caucasians and those with Diabetes Mellitus. <i>Molecular Diagnosis and Therapy</i> , 2003, 3, 355-358.	3.3	9
341	Early impairment of β -cell function and insulin sensitivity characterizes normotolerant Caucasian women with previous gestational diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 485-493.	1.1	9
342	Transcription factors of beta-cell differentiation and maturation in isolated human islets: Effects of high glucose, high free fatty acids and type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, e7-e8.	1.1	9

#	ARTICLE	IF	CITATIONS
343	Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 73-102.	1.0	9
344	Pituitary autoimmunity in patients with diabetes mellitus and other endocrine disorders. Journal of Endocrinological Investigation, 2013, 36, 127-131.	1.8	9
345	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. European Journal of Preventive Cardiology, 2020, 27, 1663-1674.	0.8	9
346	Impact of disease duration and β -cell reserve on the efficacy of switching to <i>GlarLixi</i> in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the <i>LixiLan</i> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1567-1576.	2.2	9
347	Risk factors associated with postpartum impaired glucose regulation in women with previous gestational diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107854.	1.2	9
348	Hyperalaninaemia is an early feature of diabetes secondary to total pancreatectomy. Diabetologia, 1985, 28, 277-281.	2.9	8
349	Insulin Sensitivity Is Not Impaired In Mexican-American Women Without a Family History Of Diabetes. Diabetes Care, 1995, 18, 825-833.	4.3	8
350	Pancreas transplant alone. Transplantation Proceedings, 2004, 36, 569-570.	0.3	8
351	Doxazosin in metabolically complicated hypertension. Expert Review of Cardiovascular Therapy, 2007, 5, 1027-1035.	0.6	8
352	Dysglycaemia in non-diabetic hypertensive patients: comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile. Journal of Human Hypertension, 2009, 23, 332-338.	1.0	8
353	A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. Diabetes, Obesity and Metabolism, 2019, 21, 2240-2247.	2.2	8
354	Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19?. The Lancet Healthy Longevity, 2021, 2, e6-e7.	2.0	8
355	In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertension. Diabetes, 1993, 42, 764-772.	0.3	8
356	Left ventricular mass in type 2 diabetes mellitus. A study employing a simple ECG index: The Cornell voltage. Journal of Endocrinological Investigation, 2000, 23, 139-144.	1.8	7
357	Unlocking the opportunity of tight glycaemic control. Far from goal. Diabetes, Obesity and Metabolism, 2005, 7, S1-S4.	2.2	7
358	Blood Glucose Control and Coronary Heart Disease. Herz, 2010, 35, 148-159.	0.4	7
359	Is maternal educational level a risk factor for gestational diabetes in Caucasian women?. Diabetic Medicine, 2012, 29, 416-417.	1.2	7
360	Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 886-892.	1.1	7

#	ARTICLE	IF	CITATIONS
361	Hospital incidental diagnosis of diabetes: A population study. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 457-461.	1.2	7
362	Use of non-nutritive-sweetened soft drink and risk of gestational diabetes. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108943.	1.1	7
363	Rationale for the association of sulfonylurea and insulin. <i>American Journal of Medicine</i> , 1991, 90, S77-S82.	0.6	6
364	Single-Center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous Pancreas-Kidney transplantation. <i>Transplantation Proceedings</i> , 2004, 36, 1064-1066.	0.3	6
365	Inhaled insulins: the present and future of diabetes therapy. <i>Current Medical Research and Opinion</i> , 2006, 22, S13-S19.	0.9	6
366	Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND). <i>International Journal of Clinical Practice</i> , 2010, 64, 160-168.	0.8	6
367	Functional and Survival Analysis of Isolated Human Islets. <i>Transplantation Proceedings</i> , 2010, 42, 2250-2251.	0.3	6
368	Q192R Paraoxonase (PON)1 Polymorphism, Insulin Sensitivity, and Endothelial Function in Essential Hypertensive Men. <i>Clinical Medicine Insights: Cardiology</i> , 2014, 8, CMC.S15493.	0.6	6
369	Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. <i>Postgraduate Medicine</i> , 2016, 128, 747-754.	0.9	6
370	Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes. <i>Advances in Therapy</i> , 2021, 38, 1715-1731.	1.3	6
371	Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. <i>Diabetes Care</i> , 2021, 44, 774-780.	4.3	6
372	An alternative and simple method to consistently prepare viable isolated human islets for clinical transplantation. <i>Transplantation Proceedings</i> , 2004, 36, 605-606.	0.3	5
373	Portal entericâ€drained solitary pancreas transplantation without surveillance biopsy: is it safe?. <i>Transplantation Proceedings</i> , 2004, 36, 1090-1092.	0.3	5
374	New-onset diabetes after kidney transplantation. <i>Diabetic Medicine</i> , 2005, 22, 1125-1126.	1.2	5
375	Serum gammaâ€glutamyltransferase levels are related to insulin sensitivity and secretion in subjects with abnormal glucose regulation. <i>Diabetes/Metabolism Research and Reviews</i> , 2010, 26, 181-186.	1.7	5
376	Lack of association between CYP21 V281L variant and polycystic ovary syndrome in Italian women. <i>Gynecological Endocrinology</i> , 2010, 26, 596-599.	0.7	5
377	Linagliptin for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2759-2762.	0.9	5
378	How much weight are women gaining during pregnancy? An Italian cohort study. <i>Gynecological Endocrinology</i> , 2015, 31, 942-944.	0.7	5

#	ARTICLE	IF	CITATIONS
379	Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2018, 17, 78.	2.7	5
380	Exercise during pregnancy: how much active are pregnant women at risk of gestational diabetes despite few contraindications?. <i>Gynecological Endocrinology</i> , 2021, 37, 101-104.	0.7	5
381	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. <i>Diabetes Therapy</i> , 2022, 13, 847-872.	1.2	5
382	Glycerophosphate acyltransferase activity in perfused liver of normal and hyperlipemic rats: Glucagon effect. <i>Acta Diabetologica</i> , 1981, 18, 357-363.	1.2	4
383	The combined treatment with insulin and sulfonylurea in non-insulin-dependent diabetic patients with secondary failure. <i>Diabetes Research and Clinical Practice</i> , 1988, 4, 75-81.	1.1	4
384	Improvement of Basal Hepatic Glucose Production ana Fasting Hyperglycemia of Type I Diabetic Patients Treated With Human Recombinant Ultralente Insulin. <i>Diabetes Care</i> , 1994, 17, 535-540.	4.3	4
385	Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickening. <i>Diabetes and Vascular Disease Research</i> , 2004, 1, 51-52.	0.9	4
386	Solitary pancreas transplantation: preliminary findings about early reduction of proteinuria in incipient or evident diabetic type I nephropathy. <i>Transplantation Proceedings</i> , 2004, 36, 591-596.	0.3	4
387	Correspondence Between the International Diabetes Federation Criteria for Metabolic Syndrome and Insulin Resistance in a Cohort of Italian Nondiabetic Caucasians: The GISIR database. <i>Diabetes Care</i> , 2007, 30, e33-e33.	4.3	4
388	Insulin as an Early Treatment for Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, S198-S204.	4.3	4
389	Integrating medical and surgical therapies to optimize the outcomes of type 2 diabetes. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 1186-1191.	1.0	4
390	Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). <i>Diabetes Care</i> , 2016, 39, S113-S114.	4.3	4
391	Bariatric surgery restores visual cortical plasticity in nondiabetic subjects with obesity. <i>International Journal of Obesity</i> , 2021, 45, 1821-1829.	1.6	4
392	MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance.. <i>Diabetes and Metabolism</i> , 2022, 48, 101292.	1.4	4
393	Insulin secretion and action affect glucose variability in the early stages of glucose intolerance. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3531.	1.7	4
394	Efficacy and Safety of Tirzepatide versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4). <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	4
395	Effects of Insulin Treatment on Ketone Body Production and Carnitine-Palmitoyl-Transferase (CPT) Activity in the Isolated Perfused Liver from Streptozotocin Diabetic Rats. <i>Hormone and Metabolic Research</i> , 1985, 17, 271-274.	0.7	3
396	The extracellular portion of the insulin receptor beta-subunit regulates the cellular trafficking of the insulin-insulin receptor complex. Studies on Chinese hamster ovary cells carrying the Cys 860-->Ser insulin receptor mutation. <i>European Journal of Endocrinology</i> , 2003, 148, 365-371.	1.9	3

#	ARTICLE	IF	CITATIONS
397	Solitary pancreas transplantation in wolfram syndrome1.. Transplantation, 2003, 76, 1535.	0.5	3
398	Partnering with governments and other institutions: driving change in diabetes care. International Journal of Clinical Practice, 2007, 61, 38-46.	0.8	3
399	Exenatide modulates visual cortex responses. Diabetes/Metabolism Research and Reviews, 2019, 35, e3167.	1.7	3
400	Ketone body metabolism in NIDDM. Effect of sulfonylurea treatment. Diabetes, 1992, 41, 968-974.	0.3	3
401	Type 2 Diabetes Mellitus. From the start “ combination therapy. Diabetes Mellitus, 2018, 21, 386-394.	0.5	3
402	<i>SIRT1</i> rs7896005 polymorphism affects major vascular outcomes, not all cause mortality, in Caucasians with type 2 diabetes: A 13-year observational study. Diabetes/Metabolism Research and Reviews, 2022, 38, e3523.	1.7	3
403	Retrospective analysis of daily glucose profile in type 1 diabetic patients with continuous subcutaneous insulin infusion (CSII). Diabetes Research and Clinical Practice, 1992, 16, 197-202.	1.1	2
404	Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients. Nephrology Dialysis Transplantation, 2004, 19, 2419-2420.	0.4	2
405	Simultaneous pancreas-kidney transplantation is improved by living kidney donation program. Transplantation Proceedings, 2004, 36, 1061-1063.	0.3	2
406	Pathophysiology of Insulin Action in Humans. , 2005, , 179-197.		2
407	Sulfonylureas in the therapy of type 2 diabetes mellitus: where do we stand today?. Metabolism: Clinical and Experimental, 2006, 55, S1.	1.5	2
408	When and how to restore β -cell function?. International Congress Series, 2007, 1303, 138-145.	0.2	2
409	Type 2 diabetes mellitus: focus on new treatments and special populations. International Journal of Clinical Practice, 2007, 61, 1-2.	0.8	2
410	Serum gamma-glutamyltransferase is not associated to peripheral arterial disease in type 2 diabetic patients: Cross-sectional findings. Atherosclerosis, 2009, 203, 49-50.	0.4	2
411	Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Diabetes Care, 2013, 36, S111-S112.	4.3	2
412	Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes. Lancet, The, 2014, 384, 1096.	6.3	2
413	Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious? Reply to Rigalleau V, Blanco L, Alexandre L et al [letter]. Diabetologia, 2017, 60, 2123-2125.	2.9	2
414	Rational combination therapy for type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2019, 7, 328-329.	5.5	2

#	ARTICLE	IF	CITATIONS
415	Tackling obesity during the COVID-19 pandemic. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3393.	1.7	2
416	Switching to <i>iGlarLixi</i> versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (<i>GLP-1 RA</i>) in insufficiently controlled type 2 diabetes: A <i>LixiLan</i> trial subgroup analysis by HbA1c and <i>GLP-1 RA</i> use at screening. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1331-1341.	2.2	2
417	Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 699477.	1.2	2
418	Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report. <i>Frontiers in Endocrinology</i> , 2022, 13, 847778.	1.5	2
419	Short sleep duration and risk of gestational diabetes. <i>Gynecological Endocrinology</i> , 2022, 38, 672-675.	0.7	2
420	"Do-it-yourself" insulin pump. Case report. <i>Acta Diabetologica Latina</i> , 1989, 26, 75-78.	0.2	1
421	Use of new ADA and WHO criteria for the diagnosis of impaired fasting glycemia and diabetes in kidney graft recipients. <i>Acta Diabetologica</i> , 2002, 39, 129-130.	1.2	1
422	Successful Solitary Pancreas Transplantation With Portal-Enteric Drainage Following Unsuccessful Islet Cell Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 1278-1279.	0.3	1
423	Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). <i>Diabetes Care</i> , 2011, 34, S99-S100.	4.3	1
424	Global Call for Free Academic Movement for International Dialogue. <i>Diabetes Care</i> , 2012, 35, 1631-1632.	4.3	1
425	Glucose and LDL Lowering: The Need for Intensive Therapy. <i>Current Vascular Pharmacology</i> , 2012, 10, 687-689.	0.8	1
426	Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? <i>Diabetes Care</i> 2014;37:1499-1508. <i>Diabetes Care</i> , 2014, 37, e247-e247.	4.3	1
427	Fixed-ratio combination of basal insulin and GLP-1 receptor agonist: is two better than one?. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 856-858.	5.5	1
428	Progress and change. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1.	1.2	1
429	1h post-load blood glucose for detection of individuals at increased risk of diabetes and cardiovascular disease. <i>Diabetes Research and Clinical Practice</i> , 2016, 120, 184-185.	1.1	1
430	Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy. <i>Current Medical Research and Opinion</i> , 2020, 36, 555-562.	0.9	1
431	Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. <i>Diabetes Care</i> 2020;43:e139-e141. <i>Diabetes Care</i> , 2021, 44, e81-e81.	4.3	1
432	Effect of streptozotocin in a case of glucagon-secreting malignant islets-cell tumor. <i>Journal of Endocrinological Investigation</i> , 1984, 7, 111-116.	1.8	0

#	ARTICLE	IF	CITATIONS
433	Continuous subcutaneous insulin infusion in a patient with partial endocrine pancreatic graft function. <i>Transplantation Proceedings</i> , 2001, 33, 3500-3501.	0.3	0
434	Cardiovascular risk factors in recipients of successful kidney-pancreas transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 3681.	0.3	0
435	Glucose intolerance and diabetes in recipients of kidney graft: comparison of old and new ADA and WHO criteria. <i>Transplantation Proceedings</i> , 2001, 33, 3664.	0.3	0
436	Type 2 diabetes management: putting theory into practice—introduction. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1-2.	1.5	0
437	Type 2 diabetes: simple, dual or multiple pathogenetic defects?. <i>International Congress Series</i> , 2003, 1253, 95-103.	0.2	0
438	We-P11:184 Endothelial nitric oxide synthase (ENOS) GLU298ASP and T-786C gene polymorphism and metabolic syndrome in essential hypertension. <i>Atherosclerosis Supplements</i> , 2006, 7, 386.	1.2	0
439	Î±-Adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria. <i>Journal of Hypertension</i> , 2006, 24, 1217.	0.3	0
440	Highlights from International Congress. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 91-104.	1.0	0
441	Genes, diabetes and cardiovascular risk prediction. <i>Nature Reviews Endocrinology</i> , 2009, 5, 192-193.	4.3	0
442	Prognostic implications of diabetes phenotyping: new concepts for an old disease. <i>Internal and Emergency Medicine</i> , 2009, 4, 325-329.	1.0	0
443	P4.07 DIFFERENT IMPACT OF HYPERTENSION AND TYPE 2 DIABETES ON AORTIC, CAROTID AND PERIPHERAL VASCULAR STIFFNESS. <i>Artery Research</i> , 2010, 4, 162.	0.3	0
444	2009 SIPREC Consensus Document – Executive Summary. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010, 17, 237-247.	1.0	0
445	Response Letter to D. Singh–Franco et al.. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 1054-1055.	2.2	0
446	Might hypovitaminosis D aggravate endothelial dysfunction-related increases in arterial stiffness seen in patients with hypertension and type 2 diabetes? Reply to Boucher BJ [letter]. <i>Diabetologia</i> , 2012, 55, 3142-3143.	2.9	0
447	A master course on “Methodologies for Bio-Medical research in diabetes”. <i>Archives of Physiology and Biochemistry</i> , 2013, 119, 137-138.	1.0	0
448	OP44 ORAL GLUCOSE LOWERING WITH LINAGLIPTIN PLUS METFORMIN COMPARED WITH LINAGLIPTIN ALONE AS INITIAL TREATMENT IN ASIAN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES AND MARKED HYPERGLYCEMIA. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, S22-S23.	1.1	0
449	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 1-44.	0.1	0
450	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 527-569.	0.1	0

#	ARTICLE	IF	CITATIONS
451	Ten Years of Vildagliptin. <i>European Endocrinology</i> , 2017, 13, 54.	0.8	0
452	A few clinical features improve the prediction of mortality and cardiovascular outcomes in patients with type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 2022, 28, e1-e3.	0.8	0